Semaglutide vs Tirzepatide: Mechanism, Trial Weight-Loss Data and Tolerability Compared (2026)

Semaglutide and tirzepatide are widely discussed in current metabolic and obesity research, and they are frequently discussed as if they were interchangeable variants of the same molecule. They are not. One is a selective GLP-1 receptor agonist derived from native human GLP-1. The other is a dual GIP/GLP-1 receptor agonist built on the GIP hormone backbone. The distinction matters for anyone trying to make sense of the trial literature, because the two peptides come from different clinical trial programs and were not compared head-to-head in a randomized trial until 2025.

This article lays out the mechanism, the pivotal efficacy trials, the first randomized head-to-head comparison between them, and the gastrointestinal tolerability data, all sourced from peer-reviewed publications with PMIDs. It closes with a look at where the research field is moving next: retatrutide and cagrilintide. Both semaglutide and tirzepatide are approved prescription drugs; the material sold on this site is research-grade only, and nothing here is dosing advice.

Two Molecules, Two Different Engineering Strategies

Semaglutide is a 31-amino-acid analog of native human GLP-1, modified at three points: an Aib8 substitution, an Arg34 substitution, and a C18 fatty-diacid linker attached at Lys26 that binds serum albumin. It acts on a single receptor, the GLP-1 receptor, through which it mediates its metabolic and appetite-related effects.

Tirzepatide is a distinct 39-amino-acid synthetic peptide engineered on the native GIP hormone backbone, not on GLP-1. It is engineered as a dual agonist that activates both the GIP receptor and the GLP-1 receptor, a "twincretin" design, and carries a longer C20 fatty-diacid (eicosanedioic acid) moiety for albumin binding. This is a common misconception in casual comparisons: tirzepatide is not semaglutide with an extra receptor bolted on. It is a separately engineered molecule from a different starting hormone that happens to also engage the GLP-1 receptor. The exact mechanistic contribution of concurrent GIP-receptor activity to the efficacy and tolerability differences from single-receptor agonists is still an active research question, not a settled one.

Both peptides exploit the same underlying trick to get from a native hormone half-life of minutes to a once-weekly injection: fatty-acid albumin binding. Native GLP-1 has a circulating half-life of roughly two minutes. Semaglutide's terminal half-life is approximately seven days (about 168 hours), with roughly 95% elimination around 24 days after the last dose. Tirzepatide's terminal half-life is approximately five days (about 120 hours), with roughly 95% elimination around 17 days after the last dose. Both support weekly subcutaneous dosing; semaglutide simply clears the body somewhat more slowly on the tail end.

The Pivotal Trials: STEP 1 and SURMOUNT-1

The headline weight-loss figures for each peptide come from separate, non-comparative, placebo-controlled trials in each drug's pivotal obesity program.

STEP 1 (Wilding et al., NEJM 2021, PMID 33567185) randomized 1,961 adults with overweight or obesity 2:1 to semaglutide 2.4 mg subcutaneous once weekly or placebo, both alongside a lifestyle intervention, for 68 weeks. Mean weight change was -14.9% with semaglutide versus -2.4% with placebo, an estimated treatment difference of -12.4 percentage points (95% CI -13.4 to -11.5, P less than 0.001). In absolute terms that was 15.3 kg versus 2.6 kg. Within the semaglutide arm, 86% of participants lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%, compared with 31.5% reaching at least 5% weight loss on placebo.

SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 adults with obesity or overweight, without diabetes, to tirzepatide 5 mg, 10 mg or 15 mg once weekly, or placebo, for 72 weeks. Mean weight change was -15.0%, -19.5% and -20.9% for the three doses respectively, versus -3.1% with placebo. At the 15 mg dose, 57% of participants lost at least 20% of body weight, versus 3% on placebo, and roughly 90% of participants on any tirzepatide dose lost weight. Secondary sources sometimes cite a wider "16.0% to 22.5%" range for SURMOUNT-1, drawn from different estimands or secondary analyses; this article uses the primary efficacy-estimand figures reported in the trial's own abstract (15.0%, 19.5%, 20.9%) for consistency.

The Actual Head-to-Head: SURMOUNT-5

SURMOUNT-5 (Aronne et al., NEJM 2025, PMID 40353578) is the first randomized, open-label, Phase 3b trial to compare tirzepatide and semaglutide directly, in the same population, under the same protocol. It enrolled 751 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes, and randomized them to tirzepatide (titrated to a maximum tolerated dose of 10 or 15 mg) or semaglutide (titrated to a maximum tolerated dose of 1.7 or 2.4 mg), both for 72 weeks.

Results: mean weight change was -20.2% with tirzepatide versus -13.7% with semaglutide, a between-group difference of -6.5 percentage points. Waist circumference dropped 18.4 cm with tirzepatide versus 13.0 cm with semaglutide. At least 30% weight loss was reached by 19.7% of the tirzepatide group versus 6.9% of the semaglutide group.

Tolerability: Gastrointestinal Adverse Events Compared

Gastrointestinal adverse events dominate the tolerability profile of both peptides and cluster around dose-escalation steps. In STEP 1, semaglutide 2.4 mg produced nausea in 43.9% of participants (versus 16.1% on placebo), diarrhea in 29.7% (versus 15.9%), vomiting in 24.5% (versus 6.3%) and constipation in 24.2% (versus 11.1%). The large majority of these events were mild to moderate in severity; 4.3% of the semaglutide arm discontinued permanently because of a GI adverse event.

In SURMOUNT-1, tirzepatide's nausea rate by dose (5 mg / 10 mg / 15 mg) was 24.6% / 33.3% / 31.0%, versus 9.5% on placebo. Discontinuation due to adverse events ranged from 4.3% to 7.1% across the three doses, versus 2.6% on placebo.

Raw percentages from separate trials, however, are exactly the comparison the warning callout above cautions against. The cleaner data point again comes from SURMOUNT-5, the head-to-head: GI-adverse-event-driven discontinuation was 2.7% with tirzepatide versus 5.6% with semaglutide, in the same trial, under the same protocol. In other words, in the trial designed to compare the two peptides directly, tirzepatide produced both more weight loss and fewer GI-driven dropouts, which runs against the assumption that broader receptor engagement necessarily means more side effects.

Both drug classes carry standard incretin-class warnings and contraindications: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a boxed warning associated with a thyroid C-cell tumor signal seen in rodent studies), pancreatitis risk, gallbladder disease, and rare acute kidney injury from dehydration due to GI fluid losses. In the clinical trials, both drugs used a stepwise titration schedule during the escalation phase, consistent with standard practice to mitigate GI adverse events: semaglutide started at 0.25 mg and escalated over roughly 16 to 20 weeks to a 2.4 mg maintenance dose, while tirzepatide started at 2.5 mg and escalated in 2.5 mg increments every four weeks to a 5, 10 or 15 mg maintenance dose. These figures describe the published clinical trial protocols, not a usage schedule for the research-grade material sold here.

Where the Field Is Heading: Retatrutide and Cagrilintide

Semaglutide and tirzepatide are not the end point of incretin-pathway research. Two compounds extend the same design logic in different directions, and both remain investigational.

Retatrutide (LY3437943) extends tirzepatide's dual-agonist engineering one step further: the same 39-amino-acid design strategy, but adding glucagon-receptor agonism on top of GIP and GLP-1, for a triple agonist. In a Phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315) of 338 adults with obesity over 48 weeks, the highest dose (12 mg) produced a mean weight reduction of roughly 24% versus roughly 2% on placebo, with 100%, 93% and 83% of that dose group reaching at least 5%, 10% and 15% weight loss respectively. Two caveats matter here: this is a smaller, shorter, placebo-controlled Phase 2 trial, not a head-to-head against semaglutide or tirzepatide, and retatrutide is not approved anywhere. Phase 3 (the TRIUMPH program) is ongoing as of mid-2026. For a full three-way comparison of mechanism and status, see Retatrutide vs Tirzepatide vs Semaglutide.

Cagrilintide takes a different approach entirely and is a common point of confusion: it is not another GLP-1 molecule. It is a 37-amino-acid long-acting amylin-receptor agonist, acting through a mechanistically independent satiety pathway rather than the incretin system. Coadministered with semaglutide once weekly as CagriSema, it was tested in REDEFINE 1 (Garvey et al., NEJM 2025, PMID 40544433), a trial of 3,417 adults with obesity or overweight and at least one comorbidity, without diabetes, over 68 weeks. Mean weight change was -20.4% with CagriSema versus -3.0% with placebo, a treatment difference of -17.3 percentage points, with 60% of participants reaching at least 20% weight loss and 23% reaching at least 30%. As with retatrutide, cagrilintide and CagriSema are not approved anywhere as of mid-2026; Phase 3 data has been published, and regulatory review is understood to be underway, but no FDA or EMA marketing authorization exists yet.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Cagrilintidemetabolic

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

Approved Drug vs Research Material: What This Comparison Actually Describes

Both molecules discussed here are approved prescription pharmaceuticals on both sides of the Atlantic. Semaglutide is FDA-approved as Ozempic for type 2 diabetes since 2017 and as Wegovy for chronic weight management since June 4, 2021, with a cardiovascular risk-reduction indication added in 2024; EMA approval followed the same pattern (Ozempic 2018, Wegovy 2022). Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes since May 2022 and as Zepbound for chronic weight management since November 8, 2023, with an obstructive sleep apnea indication added in 2024; EMA approved Mounjaro in September 2022, with the weight-management indication also authorized in the EU.

The approved products are specific, formulated, prescription pharmaceutical products, with regulator-audited manufacturing and delivery devices, dispensed only against a physician's prescription. The material sold on this site under the names semaglutide, tirzepatide, retatrutide and cagrilintide is research-grade, sold strictly for laboratory and research use, in a different regulatory category from the branded, prescription drugs cited throughout this article. The clinical trial data above characterizes the pharmacology of the active molecule as reported in peer-reviewed literature. It is not a claim that our research material is equivalent to, or a substitute for, Ozempic, Wegovy, Mounjaro or Zepbound.

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

Metabolic Researchmetabolic

GIP/GLP-1/Glucagon agonists and metabolic pathways

Frequently Asked Questions

This article summarizes peer-reviewed clinical trial data on the approved pharmaceutical molecules semaglutide and tirzepatide, and on the investigational compounds retatrutide and cagrilintide, for research and educational context only. It is not medical or dosing advice. The semaglutide, tirzepatide, retatrutide and cagrilintide sold on this site are research-grade material for laboratory use only, not the approved pharmaceutical products named for context.